Clinical Trials Logo

Clinical Trial Summary

Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.


Clinical Trial Description

Screening took place up to 90 days before quarantine. Volunteers completed an informed consent and underwent screening assessments to determine their eligibility.

There were 2 study groups:

Cohort A: (Sentinel): determined the Challenge Virus infection rate after inoculation with Influenza Virus on Day 0. There was 12 subjects (open label, no randomisation) invited to attend Quarantine on Day -2 or -1.

Cohort B: Examined the prophylactic efficacy, safety and tolerability of PrEP-001 compared to placebo (randomised 1:1). Subjects attended on Day -4/-3, dosed with PrEP-001 or Placebo on Day -2 AND Day-1 and then challenged with virus (volume confirmed from Cohort A) on Day 0.

Volunteers remained in quarantine unit for 8 days after inoculation.

At day 28, end of study visit, volunteers seen and assessed by a study physician for well-being, on-going symptoms and adverse events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03220048
Study type Interventional
Source Hvivo
Contact
Status Completed
Phase Phase 2
Start date September 16, 2015
Completion date February 2016

See also
  Status Clinical Trial Phase
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT03315104 - Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A Phase 2
Completed NCT04204993 - Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus) N/A
Completed NCT03743688 - Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults